Research explained
TB-500 vs Thymosin Beta-4: Identity & Human Evidence
Understand TB-500 research, how the fragment differs from thymosin beta-4, what human studies actually tested, and the limits of recovery claims.
By PurePeptideHub Research Team · Evidence updated
Editorial evidence update; independent clinical review pending. Editorial standards
Experimental fragment; do not equate it with full-length thymosin beta-4.
Evidence at a glance
Selected sources supporting this update. This is an editorial evidence summary, not a systematic review of every publication.
| Source and design | What it supports | What it cannot establish |
|---|---|---|
| Ruff et al., 2010: intravenous thymosin beta-4 in healthy volunteers Randomized placebo-controlled early safety study; 40 healthy volunteers | The study reported short-term tolerability of synthetic full-length thymosin beta-4. | It did not establish injury recovery benefits or test the LKKTETQ fragment sold as TB-500. |
| FDA: thymosin beta-4 fragment (LKKTETQ) Regulatory safety assessment | FDA identifies potential immune reactions and peptide impurity concerns for the fragment. | This is a safety assessment, not evidence of effectiveness. |
What does TB-500 refer to?
The name is used inconsistently in commercial material. FDA identifies TB-500 as the LKKTETQ fragment of thymosin beta-4. A paper studying full-length thymosin beta-4 should not be counted as direct evidence for that fragment. Check the molecular identity, sequence and formulation before comparing claims.
Compare the molecule before comparing the results
The safest reading of an ambiguous name is to leave identity unresolved until a sequence and modification specification are available. The table separates the FDA-named fragment from the full-length material in the cited human study.
| Name or material | What to identify | Which evidence applies |
|---|---|---|
| TB-500 / LKKTETQ fragment | Fragment sequence, terminal modifications and formulation | Fragment-specific research; do not borrow full-length results |
| Full-length thymosin beta-4 | The full sequence and the study’s formulation | The Ruff study assessed intravenous synthetic thymosin beta-4 |
| A product labeled only “TB-500” | Exact sequence and analytical identity | A label alone cannot establish that it matches either research preparation |
Sources: Ruff et al., 2010: intravenous thymosin beta-4 in healthy volunteers · FDA: thymosin beta-4 fragment (LKKTETQ)
Does TB-500 research prove faster injury recovery?
The cited human study evaluated early safety of a different molecular preparation. It does not answer whether TB-500 heals a tendon, treats a muscle tear or improves athletic performance. Mechanistic explanations and animal findings can motivate research, but they cannot establish a human treatment benefit.
What is known about oral bioavailability?
The intravenous study does not measure oral absorption. It cannot validate an oral product or justify substituting one route for another. A defensible absorption claim needs pharmacokinetic data for the same molecule, formulation and route.
How to evaluate a claim
Ask whether a source tested the actual fragment, used a control group, measured outcomes relevant to the claim and followed participants long enough to assess harm. A vendor certificate can describe a sample; it does not fill gaps in clinical evidence.
Common questions
Is TB-500 the same as thymosin beta-4?
Not necessarily. FDA identifies the LKKTETQ fragment as TB-500. Do not assume that studies of full-length thymosin beta-4 establish the effects of a product labeled TB-500.
Is there an established TB-500 recovery dose?
The sources assessed here do not establish a safe and effective human dose for injury recovery. This guide does not derive a dose from animal experiments or a different molecule.
Continue your research
Educational information only. This page does not recommend a medicine, dose or injection protocol. Report a correction with its source.